Phase 1RecruitingPriority 4 · Lower priorityNCT06914037
A Clinical Study of CHT101 in CD70-Positive Relapsed or Refractory Hematological Malignancies
Plain-language summary
This trial is testing CHT101 for patients with cutaneous T-cell lymphoma (CTCL), including mycosis fungoides or Sézary syndrome whose disease has come back or stopped responding to prior treatment. This is a Phase 1 trial, which means researchers are finding the right dose and this is among the earliest testing in patients. The study looks at both safety and how well the treatment controls the lymphoma. This trial does not currently have sites in the United States. The trial is currently recruiting patients.
Who can join (key eligibility)
- Age 18 Years to 70 Years years
- Lymphoma came back or did not respond to prior treatment
- Must be well enough for treatment (adequate performance status)
Final eligibility is determined by the trial team. This list is a starting point only.
What's being tested
CHT101 (DRUG): CD70 UCAR-T
CHT101
- Treatment length
- Ask the trial team for details
- Visit frequency
- Ask the trial team for details